NicOx Blood Pressure Data Positive, But Is it Enough?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Shares in France's largest biotech, NicOx, received a small boost Dec. 17 after the company reported positive blood pressure data for Phase III-hopeful naproxcinod
You may also be interested in...
Naproxcinod Can Win Approval Without Superiority Trial, NicOx Says
Facing skeptical FDA, company in partnering talks as more Phase III data with anti-inflammatory drug prove positive.
NicOx Gets Positive Results In Second Phase III Trial For Naproxcinod
In addition to meeting clinical endpoints, anti-inflammatory continues to show non-detrimental effect on blood pressure.
Nervous Times for NDA Sponsors: The New Reality of FDA Drug Reviews
FDA is adopting a broad range of procedural changes in response to suggestions from outside critics to address drug safety issues. The most significant change, however, may be just a new state of mind.